INTRODUCTION

YUSRA BHATTI
LIAQUAT UNIVERSITY OF
MEDICAL AND HEALTH
SCIENCES
PHARM –D
AIDS
• ARTICLE TOPICS:
• 1.The power of partners Positively engaging networks of the people with HIV in testing
,treatment and prevention
•Writer: David A Katz,Vincent J Wong,Amy M Medley,Rachel C Baggaley
2.Challenges in measurement of linkage following HIV self-testing
•Writer: Melissa Neuman,Miriam Taegtmeyer,Karin Harzold,Cheryl C Johnson,Helen A
Weiss,Katherine Fielding
• 3:Current and Future priorities for the development of optimal HIV drugs
Writer:Vitoria,Marco,Rangaraj,Ajay,Ford,Nathan,Doherty Meg
4.HIV prevention,treatment ,care and support for people who use stimulant drugs
Writer:UNODC,WHO,UNAIDS
5.The thine own test be true :HIV self testing and the global research for the
undiagnosed
Writer:Vincent Wong ,Erin Jenkins,Nathan Ford,Heather Ingold
SUMMARY
ARTICLE 1 (19 JULY 2019)
• HIV partner notification is a voluntary process during which a trained provider asks
people diagnosed with HIV about their sex and drug injecting partners and if the client
agrees,offers to assist in the notification and testing of these partners.
• The articles in this special issue represent a diversity of programmatic
experiences,research and community
• PNS highlight the need to provide services that meet the WHO minimum standards for
HIV test consent,confidentatily,counselling,connectiom to services and correct test
results and avoid social harm.
SUMMARY
ARTICLE 2 (MARCH 2019)
• Knowledge of HIV status through HIV testing constitutes the first step towards HIV treatment and
prevention services. HIV self‐testing (HIVST), whereby individuals collect their own specimen, conduct
their own test and interpret the results, allows individuals to learn their HIV status conveniently and
privately, as well as to decide when and where to attend post‐test services. Accurate estimation of the
proportion of those tested who link to additional HIV care, treatment and prevention services is critical
in quantifying the health impact of HIV testing. As HIVST becomes integrated into testing programmes
worldwide, implementers in diverse settings will need to measure the effectiveness of their
programmes to ensure self‐testers link to onward care and services. This can be challenging, and
community health programmes in many contexts find it difficult to track referral uptake and equity.
SUMMARY
ARTICLE 3 (FEB 2019)

•
Within a framework of evolving treatment harmonization and simplification, future
therapeutic options in development must take into consideration safety and
efficacy across a range of patient populations as well the mode of administration
in the context of lifelong therapy.
SUMMARY
ARTICLE 4 (AUGUST 2019)
•
Since the beginning of the HIV epidemic, the focus on HIV prevention, treatment
and care among people who use drugs has concentrated on the needs of people
who inject drugs, and mainly on those who inject opioids. However, data show
that there are HIV-related risks associated with the use of non-injecting stimulant
drugs, as well as with the unsafe injection of such drugs, including cocaine,
amphetamine-type stimulants (excluding MDMA), and stimulant new
psychoactive substances. Use of stimulant drugs has also been associated with
higher risk of HIV transmission through unsafe sexual behaviours in certain
subsets of key populations.
• The purpose of this publication is to provide guidance on implementing HIV,
hepatitis C and hepatitis B programmes for people who use stimulant drugs and
who are at risk of contracting these viruses.
SUMMARY
ARTICLE 5 (MARCH 2019)

• Globally, we are at an inflection point in achieving UNAIDS’ 95‐95‐95 goals for

2030. A recent Lancet editorial observed that “the last big shared challenge
remaining is testing—in every region the number of undiagnosed HIV infections
remains a substantial barrier to achieving UNAIDS targets and ending AIDS by
2030”. While UNAIDS estimates we are at 75% diagnostic coverage globally,
within this figure is great variation: between men and women, younger and older
individuals, rural and urban populations, among key populations and between
countries
• Many of the remaining undiagnosed individuals are presumably not engaging with
HIV services, and novel avenues to HIV testing services (HTS) that overcome
both stigma and structural barriers are needed: a new HIV testing paradigm is
urgently needed to reach these remaining undiagnosed individuals and effectively
link them to treatment. HIV self‐testing (HIVST) has developed substantially in
recent years and is now considered a new and critical HIV response strategy in
controlling the epidemic